US/UK/Canada

Share

Contacts

  • Mark Waugh

    CEO


    +1 (260) 804-1342

    • Links

    Pick a time period -
    Tags ( Active)

    Groundbreaking Study Highlights Enhanced Bone Formation with Novel Silicate-Containing Synthetic Bone Grafts

    Uppsala, April 11, 2025. OssDsign® AB (publ.) today announces that a new preclinical study comparing the bone-forming potential of different silicate-containing calcium phosphate synthetic bone grafts has been published in the peer-reviewed scientific journal Journal of Orthopaedic Surgery and Research. The study demonstrates that OssDsign Catalyst® is the first clinically available synthetic bone graft to successfully generate robust, functional bone in challenging avascular environments at early time points.A research team led by Professor Iain R. Gibson from the University of Aberdeen

    New preclinical data shows that OssDsign’s innovative synthetic bone graft outperforms a comparable device in bone formation following spinal fusion surgery

    OssDsign AB (publ) (“OssDsign” or the “Company”) today announced that the recently aquired orthobiological product OssDsign Catalyst (previously named Osteo[3] ZP Putty) has been evaluated in a preclinical study examining bone formation and function following spinal fusion surgery. The results show that OssDsign Catalyst induced rapid and reliable bone formation and that successful fusion was achieved in 100% of the studied subjects at 26 weeks, compared to 60% in the group where a comparable market-cleared device was used.OssDsign develops patient-specific regenerative implants aimed at

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media